OmniAb Inc OABI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OABI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.43
- Day Range
- $4.40–4.49
- 52-Week Range
- $3.14–6.72
- Bid/Ask
- $4.37 / $4.58
- Market Cap
- $524.72 Mil
- Volume/Avg
- 598,745 / 501,610
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 106
- Website
- https://www.omniab.com
Comparables
Valuation
|
Metric
|
OABI
|
ANAB
|
AURA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.66 | 5.82 | 1.58 |
Price/Sales | 13.07 | 30.24 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
OABI
ANAB
AURA
Financial Strength
|
Metric
|
OABI
|
ANAB
|
AURA
|
|---|---|---|---|
Quick Ratio | 3.93 | 10.62 | 18.30 |
Current Ratio | 4.11 | 10.87 | 18.76 |
Interest Coverage | — | −9.09 | — |
Quick Ratio
OABI
ANAB
AURA
Profitability
|
Metric
|
OABI
|
ANAB
|
AURA
|
|---|---|---|---|
Return on Assets (Normalized) | −7.75% | −23.50% | −32.93% |
Return on Equity (Normalized) | −9.40% | −75.96% | −37.86% |
Return on Invested Capital (Normalized) | −9.83% | −68.56% | −37.41% |
Return on Assets
OABI
ANAB
AURA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gdrbhddtv | Xzqh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wffscdtw | Rkzlbs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Psdfsxhx | Gcyfk | $97.8 Bil | |
MRNA
| Moderna Inc | Dcwryybv | Zflw | $41.3 Bil | |
ARGX
| argenx SE ADR | Zzvxrgp | Cbxh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cqscwhp | Zqdn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kgqjdqkt | Zjzbbs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vjmcbxpm | Xbxrlz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rjywdtphk | Cymfr | $12.5 Bil | |
INCY
| Incyte Corp | Gdfqzssf | Wsyyq | $11.6 Bil |